Capital Fund Management S.A. Novo Nordisk A S Call Options Transaction History

Capital Fund Management S.A.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$119.07 - $145.42 $7.08 Million - $8.65 Million	59,500 Added 51.16%	175,800 $20.9 Million
Q2 2024 Aug 13, 2024	BUY	$122.71 - $146.91 $5.03 Million - $6.02 Million	41,000 Added 54.45%	116,300 $16.6 Million
Q1 2024 May 15, 2024	SELL	$102.11 - $135.92 $37.9 Million - $50.4 Million	-370,900 Reduced 83.12%	75,300 $9.67 Million
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $37 Million - $44.4 Million	421,400 Added 1699.19%	446,200 $46.2 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $2.26 Million - $4.95 Million	24,800 New	24,800 $2.26 Million
Q3 2021 Nov 12, 2021	BUY	$84.42 - $106.62 $1.95 Million - $2.46 Million	23,100 Added 339.71%	29,900 $2.87 Million
Q2 2018 Aug 14, 2018	SELL	$44.29 - $50.42 $615,631 - $700,838	-13,900 Reduced 67.15%	6,800 $314,000
Q1 2018 May 15, 2018	BUY	$48.49 - $58.14 $504,296 - $604,656	10,400 Added 100.97%	20,700 $1.02 Million
Q3 2017 Nov 13, 2017	BUY	$41.15 - $49.22 $423,845 - $506,966	10,300	10,300 $496,000

1,955

318M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $195B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.